Bachem Holding AG Class B · SIX:BANB
Bachem Holding AG Class B — Investor Presentation (September 2021)
26 slides from Bachem Holding AG Class B's investor presentation, Sep 23, 2021

Slide 1: Bachem Investor Presentation
BACHEM INVESTOR PRESENTATION Date | September 23, 2021

Slide 2: Disclaimer (1/2)
DISCLAIMER (1/2) IMPORTANT: Please read the following before continuing. The following applies to this document, which has been prepared by Bachem Holding AG (the “Company” and together with its consolidated subsidiaries, the “Group”) solely for discussion purposes in relation to the Group. The info

Slide 3: Disclaimer (2/2)
DISCLAIMER (2/2) No assurances can be given that the forward-looking statements will be realized. The forward-looking statements speak only as of the date of this document. The Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statem

Slide 4: Agenda
AGENDA • Company snapshot • Summary of market opportunity • Historical financial track record and recap on H1 2021 • Update on growth strategy 4 Investor Presentation

Slide 5: Company Snapshot
COMPANY SNAPSHOT BACHEM

Slide 6: Leading Partner in TIDES
LEADING PARTNER IN TIDES • We are the world leading Peptide CDMO, with growing presence in Oligonucleotides • 1 600+ employees across six locations worldwide (Europe, America and Asia) • 50 years of Bachem – founded by Peter Grogg in 1971 • Listed in Switzerland since 1998 6 Investor Presentation

Slide 7: What We Do: Product and Customer Mix
• Peptides and oligonucleotides are complex biomolecules that open up so far undruggable therapeutic targets • We provide products for research, clinical development and commercial application to pharma and biotech customers PRODUCT MIX CUSTOMER MIX AS OF H1 2021 (1) AS OF FY2020 (2) WHAT WE DO Othe

Slide 8: Our Product Categories
COMMERCIAL API • Commercial Generics • Commercial NCEs OUR PRODUCT CATEGORIES CMC RESEARCH & DEVELOPMENT SPECIALTIES • Oligonucleotide NCEs • Amino Acid Derivatives • Peptide NCEs • Catalog Peptides • Cosmetic • Custom Peptide Synthesis • Diagnostics 8 Investor Presentation

Slide 9: Innovation Matters: NCE Pipeline
• NCE (1) pipeline with >150 projects • Focused oligonucleotide product extension • Increasing demand of synthetic vs. recombinant manufacturing • Growth driven by expanding NCE pipeline and new market approvals INNOVATION NCE PIPELINE (2) MATTERS Clinical Phase III Clinical Phase II >150 NCE Precli

Slide 10: Our Global Footprint
OUR GLOBAL FOOTPRINT (1) ST. HELENS (UK) BUBENDORF (CH) Acquired in 1999 45 employees Founded in 1971 1 063 employees TOKYO (JP) TORRANCE (CA) Acquired in 1996 Established in 2018 281 employees 4 employees VISTA (CA) SALES SPLIT Acquired in 2015 149 employees North America 51% Europe / Asia VIONNAZ

Slide 11: Sustainability Driven Business Model
SUSTAINABILITY DRIVEN BUSINESS MODEL Bachem’s commitment to making an ongoing contribution to key UN SDGs is manifested by ambitious and tangible sustainability targets Energy Consumption Global Greenhouse Gas Emissions • Reduce energy consumption per FTE by • Halve GHG emissions per FTE by 2026 20%

Slide 12: Summary of Market Opportunity
SUMMARY OF MARKET OPPORTUNITY

Slide 13: Strong Demand for Peptides Continues
STRONG DEMAND FOR PEPTIDES CONTINUES Long-Term Growth Drivers Global API Peptide Market (2) LARGE END MARKET Estimated Market Shares …Ageing population $36 billion PolyPeptide Corden Pharma ~10% ~20% Peptide Therapeutics AmbioPharm Market 2020 (1) …Outsourcing trend in Pharma ~10% and Biotech Bachem

Slide 14: The Oligonucleotides Opportunity
THE OLIGONUCLEOTIDES OPPORTUNITY 800 Oligos in Pipeline (2) ~$900M 10-20% Approved & Pre-Registered Global market for Est. market Phase 3 Oligos API (1) growth p.a. (1) Phase 2 • Strong synergies with peptides Phase 1 • Leading CDMOs currently Agilent and Aji-Bio IND/CTA Oligonucleotides are • 800 O

Slide 15: Oligonucleotides on the Path to Success
OLIGONUCLEOTIDES ON THE PATH TO SUCCESS Today Strategic Ambition • Oligo business successfully • Development of a second launched from mid-2010s on strategic pillar next to peptides • Full-service manufacturer for all • Expanding commercial activities clinical phases and commercial • Mid-term goal o

Slide 16: Historical Financial Track Record and H1 Recap
HISTORICAL FINANCIAL TRACK RECORD AND H1 RECAP

Slide 17: 2020 Financial Highlights
2020 FINANCIAL HIGHLIGHTS First-time sales of 14% sales CAGR CHF 123 million EBITDA > CHF 400 million from 2016-20 > CHF 500 million CHF 115 million > 30% EBITDA margin investment planned for operating cash flow 2022-26 17 Investor Presentation

Slide 18: Strong Revenue Growth Across All Product Categories and Regions
STRONG REVENUE GROWTH ACROSS ALL PRODUCT CATEGORIES AND REGIONS Sales • Capital increase in 2019 laid foundations (in CHF million) CAGR for expansion of production capacity to 14.0% capture sector growth trends 450 30% • Strong average annual growth of 14.0% 402 400 28.1% 25% 350 314 (2016-2020) 283

Slide 19: Continuously Improving Margins
CONTINUOUSLY IMPROVING MARGINS EBIT(DA) • Improving profitability margins, with (in CHF million) strong boost in 2020 on EBIT level 140 35% 123 • Ramping-up of “Operational Excellence” 30.5% 120 27.4% 27.3% 27.6% 27.8% 30% 97 allowed for stronger COGS improvement 100 24.0% 25% 87 • Favourable produc

Slide 20: Further Strong Growth and High Profitability in H1 2021
FURTHER STRONG GROWTH AND HIGH PROFITABILITY IN H1 2021 Sales • H1 2021 Sales of CHF 239.1 million (+ 35.0%) (in CHF million) • Growth across all product categories & geographies 250 35.0% 239 • Growth driven by Commercial API (62.0% of sales), 200 177 CMC (28.6% of sales) and Research & Specialties

Slide 21: Update on Growth Strategy
UPDATE ON GROWTH STRATEGY BACHEM

Slide 22: Bachem: A Long-Term Success Story
BACHEM: A LONG-TERM SUCCESS STORY Outlook 2021 Medium-term goals: 3-5 years Long-term goals: > 5 years • Expected sales of CHF 500 million in 2021 • Average annual growth of about 15% • Expand market leadership in peptides • Continued profit margin expansion • Reach CHF 100 million oligo sales • Be

Slide 23: Substantial Capex Program
SUBSTANTIAL CAPEX PROGRAM • Capex > CHF 500 million over next five years • Ongoing capacity expansion across all sites and businesses • Further invest in: • construction of hitherto largest manufacturing facility in Bubendorf • expansion of automated manufacturing solutions as well as equipment and

Slide 24: Bubendorf – Ongoing and Planned Capacity Expansion
BUBENDORF – ONGOING AND PLANNED CAPACITY EXPANSION / SITE DEVELOPMENT* New large-scale GMP Production Building K Large Annex to Building G Small Annex to Building G Existing R&D Building A Existing Existing Production Building E for starting materials (LPPS) Future expansion Expansion of Production

Slide 25: Potential Avenues to Accelerate Growth via M&A and/or Technology Synergies
POTENTIAL AVENUES TO ACCELERATE GROWTH VIA M&A AND/OR TECHNOLOGY SYNERGIES SELECTION CRITERIA EXISTING MARKETS POTENTIAL GROWTH AREAS + Strategic fit + Market potential + Technological barriers to entry mRNA Peptides + Growth profile + Profitability Lipids + Buy vs. Develop Oligos 25 Investor Presen

Slide 26: Extraordinary General Meeting Proposal
• Proposal to the Extraordinary General Meeting of Bachem for a change in the articles of association and creation of authorized capital authorizing the board of directors to issue EXTRAORDINARY up to 1 million new shares GENERAL • The authorized share capital represents approx. 7% of MEETING curren
Source: Internet Archive copy of bachem.com
More decks from Bachem Holding AG Class B
H1 2026 Earnings Presentation24 slides · Jul 30, 2026
FY2025 Earnings Presentation31 slides · Mar 12, 2026
J.P. Morgan 44th Annual Healthcare Conference 202621 slides · Jan 14, 2026
44th Annual J.P. Morgan Healthcare Conference (January 2026)21 slides · Jan 14, 2026
Investor Day (November 2024)40 slides · Nov 21, 2024
FY2023 Earnings Presentation30 slides · Mar 7, 2024